Business & Regulation

We take a deep dive into key industry trends off the back of Clarivate’s Drugs to Watch 2025 report

In part 2 of our roundtable discussion, thought leaders discuss what Trump could do for drug pricing and whether change is to be feared or embraced.

We speak with Clarivate about their report listing eleven key drugs to watch in 2025.

Biden pushed drug pricing reforms, whereas Trump is known for deregulation. What does this mean for pharma?

Radiopharmaceuticals are a promising approach to cancer, but some countries are lagging behind. A collaboration hopes to change that.

The career path of Moncef Slaoui has resulted in billions of doses of lifesaving vaccines. Here he shares his story.

To shareholders – according to an analysis of financial reports from healthcare companies.

A regulatory science push in the UK includes centres for digital transformation, AI and more.

Robert F Kennedy Jr’s recent speech suggests that investigations into childhood vaccines and over-medication could be on the cards.

The Access to Medicine Foundation has developed the 2026 AMR Benchmark to recognize and promote urgency in the ongoing AMR challenge.